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a b s t r a c t
Macrophages express low levels of the CD4 receptor compared to T-cells. Macrophage-tropic HIV strains
replicating in brain of untreated patients with HIV-associated dementia (HAD) express Envs that are
adapted to overcome this restriction through mechanisms that are poorly understood. Here, bioinfor-
matic analysis of env sequence datasets together with functional studies identiﬁed polymorphisms in the
β3 strand of the HIV gp120 bridging sheet that increase M-tropism. D197, which results in loss of an
N-glycan located near the HIV Env trimer apex, was detected in brain in some HAD patients, while
position 200 was estimated to be under positive selection. D197 and T/V200 increased fusion and
infection of cells expressing low CD4 by enhancing gp120 binding to CCR5. These results identify
polymorphisms in the HIV gp120 bridging sheet that overcome the restriction to macrophage infection
imposed by low CD4 through enhanced gp120–CCR5 interactions, thereby promoting infection of brain
and other macrophage-rich tissues.
& 2015 Elsevier Inc. All rights reserved.
Background
Macrophages are important target cells of Human immunode-
ﬁciency virus type I (HIV) infection that contribute to establish-
ment and persistence of viral reservoirs in the brain, spleen, lung,
gut, and bone marrow (Gorry et al., 2005; Pierson et al., 2000).
HIV-infected macrophages in the brain play an important role in
the development of HIV-associated dementia (HAD), a complica-
tion that can occur in patients with non-suppressed viral replica-
tion, and also represent a barrier to virus eradication due to
limited penetration by most antiretroviral therapies (Dayton,
2008; Duncan and Sattentau, 2011; Gorry et al., 2005; Le Douce
et al., 2010; Smurzynski et al., 2011).
The major determinant of HIV tropism for CD4þ T cells and
macrophages is the viral envelope glycoprotein (Env). HIV Env,
which consists of a surface-exposed gp120 and a transmembrane
gp41 subunit, is organized into trimers on the surface of virions
and infected cells (Liu et al., 2008). The gp120 subunit core is
composed of an inner domain, a heavily glycosylated outer
domain, and four surface-exposed variable loops that extend from
the core and partially occlude the coreceptor binding site and
neutralization epitopes (Dey et al., 2007; Moore and Sodroski,
1996). HIV entry into cells is initiated by a high afﬁnity interaction
between gp120 and CD4, which induces conformational changes
in gp120 (Doms and Trono, 2000). In the CD4-bound state, the
inner and outer domains come together via formation of the
bridging sheet, which is comprised of two β strands from the
inner domain (β2 and β3) and two from the outer domain (β20
and β21), resulting in formation of the coreceptor binding site. In
crystal and cryo-EM structures of soluble cleaved HIV Env trimers,
the arrangement of the CD4-induced bridging sheet appears to be
different compared to how it is shown on monomeric gp120
(Julien et al., 2013; Lyumkis et al., 2013). In the trimer structures,
β2 and β3 are only partially involved in forming the bridging sheet
with β20 and β21, and extend toward the trimer apex into the base
of the V1/V2 variable loops.
CCR5 is the primary coreceptor for virus entry into macro-
phages and microglia. However, CCR5 usage per se is not sufﬁcient
to predict macrophage tropism (M-tropism) (Cheng-Mayer et al.,
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1997; Gorry et al., 2001). Furthermore, M-tropism of CCR5-using
(R5) HIV isolates is a continuous rather than binary phenotype,
with up to 1000-fold variation among different strains in their
ability to replicate in primary monocyte-derived macrophages
(MDM) (Duncan and Sattentau, 2011; Gorry et al., 2001; Peters
et al., 2004; Richards et al., 2010; Thomas et al., 2007). One factor
contributing to this wide spectrum of M-tropism is receptor
density (Kuhmann et al., 2000; Platt et al., 1998). Macrophages
express lower levels of CD4 than CD4þ T cells in blood (Wang
et al., 2002) and are preferentially infected by viruses that can
utilize low CD4 to mediate fusion and entry (Bannert et al., 2000;
Duenas-Decamp et al., 2008; Dunfee et al., 2006b; Gorry et al.,
2002; Gray et al., 2005; Martin-Garcia et al., 2006; Peters et al.,
2004; Walter et al., 2005). Determinants of reduced CD4-
dependence or CD4-independence have been mapped to the HIV
and SIV gp120 V1/V2, V3, and V4 variable loops, C2 and C3 regions,
and regions of gp41 (Chenine et al., 2002; Dunfee et al., 2006b,
2007; Kolchinsky et al., 2001a; Otto et al., 2003; Puffer et al., 2004;
Walter et al., 2005; Yen et al., in press). These determinants
enhance Env interactions with CD4 through different mechanisms
that include increased gp120 afﬁnity for CD4 or exposure of the
CD4-binding site (Duenas-Decamp et al., 2009; Dunfee et al.,
2006b, 2007; Martin-Garcia et al., 2006; Peters et al., 2008;
Sterjovski et al., 2007), which in turn can enhance bridging sheet
recruitment (O’Connell et al., 2013).
Another mechanism that allows HIV Envs to overcome the
restriction imposed by reduced CD4 on macrophages is enhanced
gp120 interactions with CCR5. Although previous studies
described M-tropic Envs with reduced CCR5 dependence, genetic
determinants that inﬂuence this phenotype in M-tropic Envs are
poorly understood (Gorry et al., 2002; Peters et al., 2007;
Sterjovski et al., 2010; Thomas et al., 2007). Genetic determinants
that enhance gp120–CCR5 interactions in a strain-dependent
manner have been mapped to the CCR5-binding site, which
includes residues in the V3 loop, inner domain, and bridging sheet
formed by the β20/β21 strands and surface-exposed β2/β3
strands, which assemble into a hairpin to form the stem of the
V1/V2 loop (Chen et al., 2005; Kwong et al., 2000; Reeves et al.,
2002; Sterjovski et al., 2007). Residues in the bridging sheet can
impact gp120 interactions with CCR5 via direct contacts with CCR5
or by repositioning the V1/V2 loops, which occlude the CCR5
binding site in the unliganded conformation (Kolchinsky et al.,
2001a; Pan et al., 2005; Rizzuto et al., 1998; Zhu et al., 2001).
Mutations in the β20/β21 strands that disrupt the hairpin struc-
ture eliminate gp120 binding to CCR5, while genetic determinants
in β3 can inﬂuence Env–CCR5 binding (Rizzuto et al., 1998). Crystal
and cryo-EM structures of a soluble cleaved HIV Env trimer
suggest that interactions between V1/V2 and V3 at the top of
the trimer stabilize the trimer apex around the three-fold axis
(Julien et al., 2013; Lyumkis et al., 2013). Amino acids near the
trimer apex, including residues in β2 and β3, have the potential to
inﬂuence Env–CCR5 interactions given proximity to V1/V2 and V3
in the same and adjacent protomers.
Here, bioinformatic analysis of HIV env sequence datasets
from brain and blood/lymphoid compartments together with
functional studies identiﬁed rare polymorphisms in the β3 strand
of the gp120 bridging sheet that can increase virus entry into
macrophages. D197, which eliminates an N-linked glycosylation
site, was detected in brain in some HAD patients, while position
200 was estimated to be under positive selection. Mutagenesis
studies showed that D197 and T/V200 can enhance macrophage
tropism by increasing gp120 interactions with CCR5. These
ﬁndings identify naturally occurring variants in the β3 strand of
the HIV gp120 bridging sheet that can overcome the restriction to
macrophage infection imposed by low CD4 by enhancing gp120–
CCR5 interactions.
Results
Bioinformatic analysis of HIV env sequence datasets identiﬁes
polymorphisms in the gp120 bridging sheet in brain from some
patients with HIV-associated dementia
The genetic evolution of HIV variants in brain is distinct from
that in lymphoid tissues and other organs (Dunfee et al., 2006a;
Gartner et al., 1997; Lamers et al., 2009; Ohagen et al., 2003; Power
et al., 1995; Thomas et al., 2007; Wang et al., 2001). Diversifying
evolution associated with CNS infection can result in nonsynon-
ymous substitutions that affect protein structure and function, and
positive selection for polymorphisms that increase viral ﬁtness in
brain (Gray et al., 2011; Huang et al., 2002; Pond et al., 2008; Poon
et al., 2007). Viruses that can utilize low receptor levels to enter
macrophages are expected to have a selective advantage during
HIV replication in the brain. We therefore hypothesized that sites
under positive selection in the gp120 bridging sheet region of
the CCR5-binding site may represent naturally occurring variants
that could enhance M-tropism through enhanced interactions
with CCR5.
To identify sites under positive selection in the gp120 bridging
sheet, we analyzed brain- and blood/lymphoid-derived gp120
sequences using a dataset from 30 patients with or without HAD
from 10 published studies (n¼336 unique sequences from 19 HAD
subjects and 119 from 11 non-HAD subjects) (Anand et al., 1989;
Brown et al., 2011; Lamers et al., 2009; Liu et al., 2000; Martin-
Garcia et al., 2006; Mefford et al., 2008; Ohagen et al., 2003; Peters
et al., 2004; Shapshak et al., 1999; Thomas et al., 2007). Criteria for
inclusion in the dataset were availability of gp120 V1–V5
sequences with sequence coverage of all four β-strands of the
bridging sheet. Three codon-based maximum likelihood methods
(SLAC, FEL, and IFEL, http://datamonkey.org) were used to estimate
the dN/dS ratio at each codon position to calculate the probability
that codon variation was due to positive selection (Pond and Frost,
2005; Pond et al., 2006; Poon et al., 2009). In HAD patients, a total
of 51 codons were estimated to be under positive selection
(po0.05 by at least 2 methods), 29 and 27 codons in brain- and
blood/lymphoid-derived sequences, respectively (hereafter refe-
rred to as brain and lymphoid sequences) (Fig. 1A and Additional
ﬁle 1). In the bridging sheet, position 200, located in the surface-
exposed β3 strand near the trimer apex, was estimated to be
under positive selection (p¼0.02 and 0.005 in brain and lymphoid
sequences from HAD patients, respectively) (Fig. 1, Table 1, and
Additional ﬁle 1). We did not detect positive selection at position
200 in the dataset from non-HAD patients, which contains fewer
sequences and subjects (Table 1 and Additional ﬁle 1).
Next, we performed an exploratory analysis of sequences in the
β2/β3 region using the complete dataset of 796 matched brain and
lymphoid sequences from 26 patients (n¼498 brain sequences,
range 3–89 sequences/patient; median¼8 sequences/patient; and
298 lymphoid sequences, range 2–57 sequences/patient; median
5 sequences/patient) (Brown et al., 2011; Duenas-Decamp et al.,
2009; Hughes et al., 1997; Keele et al., 2008; Lamers et al., 2009;
Liu et al., 2000; Martin-Garcia et al., 2006; Mefford et al., 2008;
Morris et al., 1999; Ohagen et al., 2003; Peters et al., 2004; Thomas
et al., 2007), accounting for the variable number of sequences per
patient by weighting amino acid distributions within each patient
using stratiﬁed 22 contingency tables and normalizing for
between-patient differences in sequence depth. This exploratory
analysis revealed that loss of the N-linked glycosylation site
(PNGS) at position 197 near the trimer apex (Fig. 1B) was more
frequent in brain than in lymphoid sequences (p¼0.03, Fisher's
exact test). Filtering the dataset on one randomly selected
sequence per patient followed by analysis of β3 amino acid
distributions in the reduced dataset conﬁrmed our initial ﬁnding
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that loss of the PNGS at position 197 was more frequent in brain
compared to lymphoid tissues in these patients (Table 2), although
this difference was not statistically signiﬁcant (p40.05, Fisher's
exact test).
To determine if these β2/β3 polymorphisms near the Env
trimer apex occur in patients with HAD, we compiled a second
dataset containing β2/β3 sequences from brain of patients with or
without HAD (n¼419 brain sequences from HAD patients, range
1–89 sequences/patient; median¼5 sequences/patient; and 163
brain sequences from non-HAD patients, range 1–81 sequences/
patient; median 4 sequences/patient) (Anand et al., 1989; Lamers
et al., 2009; Liu et al., 2000; Mefford et al., 2008; Monken et al.,
1995; Morris et al., 1999; Ohagen et al., 2003; Shapshak et al.,
1999; Thomas et al., 2007). In the complete sequence dataset of
582 sequences from 45 patients, loss of the PNGS at 197 was
detected in 10% of brain sequences from 27 HAD patients and 0% of
brain sequences from 18 non-HAD patients (p¼0.001, Fisher's
exact test). Analysis of β3 amino acid distributions in a reduced
dataset of one randomly selected sequence per patient conﬁrmed
that loss of the PNGS at position 197 was more frequent in HAD
patients (Table 2), although this difference was not statistically
signiﬁcant (p40.05, Fisher's exact test). Thus, loss of the PNGS at
position 197 in β3, located near position 200 (Fig. 1C), is a rare
variant in the brain in some patients with HAD.
gp120 polymorphisms at 197 and 200 can enhance macrophage entry
by reducing dependence on CD4
Many N-linked glycans that comprise the “glycan shield” of the
gp120 outer domain are highly conserved and essential for proper
protein folding, stability, and interactions between gp120, CD4,
and CCR5 (Dey et al., 2007; Poon et al., 2007). In vitro studies
suggest that loss of speciﬁc PNGS sites in the V1/V2 loop region,
including position 197, can affect viral replication or sensitivity to
Fig. 1. Bioinformatic analysis of HIV env sequence datasets identiﬁes position 200 in the β3 strand as a site in the gp120 bridging sheet estimated to be under positive
selection in Envs from brain or blood/lymphoid tissues of HAD patients. (A) Brain and lymphoid Env sequences from patients with HAD were aligned using ClustalX2 (n¼336
brain sequences and 171 blood/lymphoid sequences from 19 HAD patients). dN–dS values were estimated by SLAC, FEL, and IFEL and normalized by total codon tree length
(http://datamonkey.org). dN–dS values are shown only for sites under positive selection, with averages calculated for any codon with po0.05 by at least 2 of the 3 programs.
Sites in brain sequences are in red, in lymphoid sequences in blue, and in both brain and lymphoid sequences in black. Locations of β strands in the bridging sheet are
indicated by horizontal arrows (β2, 120–125; β3, 196–202; β20, 423–426; β21, 429–435). Codons were numbered according to codon env position of HIV-1 HXB2 reference
strain. Vertical arrow indicates position 200 in the β3 strand. (B) Model showing the V1V2 (green), V3 (blue), and β2/β3 regions (red) in a HIV gp120 crystal structure from a
soluble cleaved HIV Env trimer (Julien et al., 2013) viewed down the trimer axis. Amino acids at positions 197 and 200 in β3 are located near the trimer apex (N and A,
respectively, in the published structure; these amino acids and glycans at the N197 N-glycosylation site are colored orange) (Julien et al., 2013; Lyumkis et al., 2013). (C) HIV
gp120 bridging sheet region depicted on the CD4-liganded HIV YU2 gp120 core structure (top ﬁgure) (Kwong et al., 2000). This structure was selected for modeling because
it is derived from a macrophage-tropic HIV-1 primary isolate and includes residues at positions 197 and 200. HIV gp120 is shown in blue, CD4 is shown in yellow. Fab 17b
was removed for clarity. β3 strand is shown in light blue. A backbone model of the β2/β3 strands of CD4-bound YU2 gp120 is shown in the bottom panel. Clade B consensus
amino acids are shown at positions 197 (green, with N-glycan in white) and 200 (orange).
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antibody neutralization (Huang et al., 2012; Igarashi et al., 2003;
Kolchinsky et al., 2001b; Ly and Stamatatos, 2000; Pikora et al.,
2005). Previous studies investigated the role of the PNGS at
position 197 in primary and lab-adapted Envs in determining
neutralization sensitivity/resistance (summarized in Table 3);
effects of variants at or near this position were strain-dependent,
but nonetheless suggested that loss of the PNGS at this position
can inﬂuence interactions with CD4 and/or CCR5. However, the
role of these variants in M-tropism is unknown. To address this
question, we introduced N197D (most common variant in brain)
and V200T into a brain-derived Env cloned from a weakly
M-tropic HIV isolate (MACS2br13, hereafter referred to as M2br)
and reciprocal changes to the clade B consensus amino acid
(D197N and T200V) into a highly M-tropic Env cloned from
autopsy brain tissue (UK1br2-14, hereafter referred to as UK1br)
(Fig. 2A) (Dunfee et al., 2006b; Gorry et al., 2002; Thomas et al.,
2007). Additionally, a double mutant (N197D/V200T) expressing
both determinants was introduced into M2br. The parental and
mutant Envs were expressed and processed from gp160 to gp120
at similar levels (Fig. 2B). Viruses expressing parental and mutant
Envs mediated similar levels of virus entry into TZM-bl cells
expressing high CD4 and CCR5, and viruses expressing UK1br
Envs mediated high levels of entry, comparable to those mediated
by the control M-tropic Env, ADA (Fig. 2C). M2br N197D and
N197D/V200T mediated increased entry into MDM, while M2br
V200T mediated similar entry, compared to the parental M2br Env
(po0.01) (Fig. 2D). UK1br T200V exhibited increased entry into
MDM, while UK1br D197N mediated similar entry, compared to
the parental UK1br Env (p¼0.05) (Fig. 2D). These results
suggest that β3 polymorphisms can inﬂuence HIV entry into
macrophages.
Next, we tested the capacity of Envs to mediate fusion with
cells expressing low levels of CD4 (Fig. 3A) (Gorry et al., 2002). The
two parental Envs mediated fusion with cells expressing low levels
of CD4 at r20% of the levels observed for cells expressing high
CD4 (Fig. 3B). In M2br Env, N197D and N197D/V200T enhanced the
overall efﬁciency of fusion over a range of CD4 levels compared to
the parental Env (p¼0.14, 0.03, and 0.06 for N197D and 0.03, 0.05,
and 0.02 for N197D/V200T, for cells expressing low, intermediate,
and high CD4, respectively), whereas the V200T change alone had
no signiﬁcant effect (Fig. 3C). Compared to T283N, a C2 variant
associated with brain infection and macrophage-tropism in pre-
vious studies (Dunfee et al., 2006b), fusion mediated by M2br
N197D/V200T at the low CD4 levels was even more efﬁcient
(Additional ﬁle 2). However, M2br N197D/V200T was not CD4-
independent. In UK1br Env, T200V increased fusion with cells
expressing intermediate levels of CD4 compared to the parental
Env, but no enhancement was observed at low CD4. UK1br D197N
exhibited decreased fusion with cells expressing low CD4 com-
pared to the parental Env (Fig. 3D). Thus, D197 and T/V200 can
increase macrophage tropism by reducing dependence on CD4.
Table 1
Position 200 in the β3 strand in the gp120 bridging sheet is estimated to be under
positive selection in HAD patients.
Alignment Codon Region Average dN–dS Average p-valuea
HAD brainb 200 β3 0.8 0.021 (FEL, IFEL)
HAD lymphoidc 200 β3 2.6 0.005 (SLAC, FEL, IFEL)
Non-HAD braind NS ΝS NS NS
Non-HAD
lymphoide
NS ΝS NS NS
NS: Not signiﬁcant (p40.05).
a SLAC, FEL, and IFEL analyses (〈http://datamonkey.org〉) were used to recon-
struct ancestral sequences at each node of a phylogenetic tree. Substitutions are
calculated at each branch and terminal node. p-Values are averaged for methods in
parentheses.
b n¼336 unique brain-derived gp120 V1–V5 region sequences from 19 HAD
subjects.
c n¼171 unique blood/lymphoid-derived gp120 V1–V5 region sequences from
15 HAD subjects.
d n¼119 unique brain-derived gp120 V1–V5 region sequences from 11 non-
HAD subjects.
e n¼66 unique blood/lymphoid-derived gp120 V1–V5 region sequences from
7 non-HAD subjects.
Table 2
Loss of N-linked glycosylation site at position 197 in the HIV gp120 β3 strand is
detected in brain in some patients with HAD.
Variant amino acid frequencya
197Ψb A198c T199c T200c V201c A202c
By tissue
Brain (n¼26) 12% (3) 4% (1) 0% (0) 15% (4) 8% (2) 0% (0)
Blood/Lymphoid (n¼26) 0% (0) 4% (1) 0% (0) 12% (3) 8% (2) 0% (0)
Brain, by diseased
HAD (n¼27) 15% (4) 4% (1) 0% (0) 7% (2) 4% (1) 0% (0)
Non-HAD (n¼18) 0% (0) 0% (0) 0% (0) 11% (2) 5% (1) 0% (0)
a Variant amino acid frequency calculated as number of sequences containing
most common variant/number of sequences containing any other amino acid
(including clade B consensus amino acid) for each position in the reduced sequence
dataset of matched brain and lymphoid sequences from 26 subjects after ﬁltering
on one randomly selected sequence per patient. Number in parentheses corre-
sponds to the number of sequences containing the variant.
b Ψ indicates the presence of any amino acid that results in elimination of the
N-linked glycosylation site.
c Amino acid designation reﬂects the most common variant at each position.
d Brain-derived sequences from 27 HAD and 18 non-HAD subjects after ﬁltering on
one randomly selected sequence per patient.
Table 3
Summary of published mutagenesis studies of sequence polymorphisms in the β3 strand of HIV gp120.
Env M-tropic Position
197a
Position
200a
Infectivityb Increased binding/
Neutralizationc
Decreased binding/
Neutralizationc
Reference
ADA Yes N197S T200 Increased (CD4-
independence)
sCD4, 17b, 19b, F105 None (Kolchinsky et al., 2001b)
YU2 Yes N197D V200 ND CD4, CCR5, F105 17b, CG10 (Rizzuto et al., 1998)
89.6 Yes N197Q V200 Increased (CD4-
independence)
sCD4, 17b, b12, 447-52d None (Li et al., 2008)
JRCSF No N197A V200 ND 2G12 sCD4, b12, b3 (Pantophlet et al., 2003; Saphire
et al., 2001)
SF162 Yes N197Q V200 Decreased in macrophages,
JC10 HeLa
IgGCD4, b12, patient sera None (Ly and Stamatatos, 2000)
YU2 Yes N197 V200S ND None sCD4, CCR5, CG10 (Rizzuto et al., 1998)
a Mutated residues in each Env are highlighted in blue.
b ND, not determined.
c Changes in binding or neutralization sensitivity to soluble CD4, CCR5, or monoclonal antibody 17b are highlighted in red.
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D197 and T/V200 can enhance fusion and virus entry in cells
expressing low CD4
We next used Afﬁnoﬁle cells (Johnston et al., 2009), a dually
inducible HEK293 cell line with independent regulation of CD4
and CCR5 expression, to investigate whether Envs with enhanced
capacity to mediate fusion with cells expressing low CD4 can
mediate enhanced entry into cells expressing low CD4 and CCR5.
Using 3 serial dilutions each of doxycyline and Ponasterone A to
regulate CD4 and CCR5 expression, respectively, created a matrix
of 9 conditions to analyze CD4 and CCR5 usage (Fig. 4A). Initial
experiments were performed using a wide range of CD4 and CCR5
expression levels; on the basis of these experiments, experimental
conditions shown in Fig. 4 were selected for subsequent experi-
ments because they detected a wide range of infectivity. Further-
more, based on standard curves of Quantibrite beads we estimated
antibody binding sites were in the range of 9104 CD4 mole-
cules on “high” cells, 3104 CD4 molecules on “intermediate”
cells, and 1104 CD4 molecules on “low” cells, which overlaps the
range of values previously detected on human primary activated T
Fig. 2. Sequence polymorphisms at positions 197 and 200 in the β3 strand of the gp120 bridging sheet can enhance macrophage entry. (A) HIV UK1br and M2br gp120 β3
sequences (Dunfee et al., 2007; Gorry et al., 2002) were aligned against the clade B consensus sequence. Dots represent residues identical to the clade B consensus. Positions
197 and 200 are shown in red. (B) 293T cells transfected with pCR3.1 Env expression plasmids analyzed by Western blotting with goat anti-gp120. ADA and YU2 Envs were
included as controls. (C) TZM-bl cells expressing high levels of CD4 and CCR5 were infected with HIV luciferase reporter viruses expressing UK1br and M2br parental or
mutant Envs, lysed 48 h after infection, and analyzed for luciferase activity. (D) Monocyte-derived macrophages (MDM) were infected with reporter viruses expressing
parental and mutant Envs, lysed 6 days after infection, and analyzed for luciferase activity. For C and D, relative luciferase units (RLU) with background subtracted are shown
for viruses expressing no Env (mock), ADA, UK1br, and M2br Envs on the left. Data on the right are presented as percentage of wild-type entry and represent duplicate wells
of a single experiment. Error bars represent standard deviations. Experiments were repeated a minimum of 3 times for each Env set. *po0.05, Student's t-test.
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lymphocytes, monocytes, and MDM, respectively, and in the range
of 5104 CCR5 molecules for “intermediate” cells, which overlaps
the range of values previously detected on MDM. UK1br Env
mediated similar entry into cells expressing low CD4 and CCR5
compared to ADA Env, while M2br Env mediated reduced entry into
cells expressing low CD4 (Fig. 4B and C). The sensitivity of M2br
N197D, V200T, and N197D/V200T to changes in cell surface CD4
and CCR5 expression differed from those of the parental M2br Env,
with these mutant Envs exhibiting increased entry into cells
expressing low CD4 and CCR5 (indicated by decreased blue and/
or green areas in the low CD4/low CCR5 quadrant) (Fig. 4B). M2br
V200T was less sensitive to low CCR5 than N197D, but more
sensitive to low CD4 than the double mutant, suggesting that both
changes contribute to the ability of M2br N197D/V200T to infect
cells expressing low CD4/low CCR5. UK1br T200V mediated
increased entry into cells expressing low CD4/low CCR5 compared
to the parental UKIbr (indicated by increased green area in the low
CD4/low CCR5 quadrant and increased orange area in the low CD4/
high CCR5 quadrant). In contrast, UK1br D197N exhibited increased
dependence on CD4 and CCR5 (indicated by increased blue area in
the low CD4/low CCR5 quadrant and right side of contour plot)
(Fig. 4B). M2br N197D/V200T and UK1br T200V mediated increased
entry into Afﬁnoﬁle cells expressing low CD4/high CCR5 and high
CD4/medium CCR5 (po0.05) (Fig. 4C), while M2br N197D and
UK1br D197N showed trends toward increased and decreased
entry, respectively, with cells expressing low CD4/high CCR5
(p¼0.09 and 0.09, respectively), consistent with results from fusion
assays (Fig. 3).
Polymorphisms at positions 197 and 200 increase gp120 interactions
with CCR5
In a previous study, Envs cloned from patient UK1 primary
brain isolates were shown to bind with high afﬁnity to CCR5
in vitro (Gorry et al., 2002). UK1br T200V mediated increased
entry into cells expressing low levels of CCR5 compared to the
parental UK1br Env. Therefore, we investigated whether this
variant increases binding of UK1br soluble gp120 to cell-surface
CCR5. UK1br T200V soluble gp120 bound to CF2th–synCCR5 cells
expressing high CCR5 with a 3-fold increase in the presence of
sCD4 and 10-fold increase in the absence of sCD4 compared to the
parental soluble gp120 (Fig. 5). This binding was inhibited by pre-
incubation with the CCR5 inhibitor TAK-779 (data not shown).
These results suggest that enhanced fusion and infection of cells
expressing low CD4 by UK1br T200V is due at least in part to
enhanced gp120 binding to CCR5.
N-linked glycosylation is important for maintaining Env
structure and occluding conserved epitopes, including the
CCR5-binding site, from neutralizing antibodies (Huang et al.,
2012; Liu et al., 2011; Musich et al., 2011; Watkins et al., 2011).
Loss of the PNGS at position 197 inﬂuences HIV sensitivity to
neutralizing inhibitors and antibodies, including sCD4, 17b, and
b12, in a strain-dependent manner (Table 3) (Huang et al., 2012;
Kolchinsky et al., 2001a; Li et al., 2008; Rizzuto et al., 1998).
Therefore, we measured neutralization sensitivity of the par-
ental and mutant Envs to soluble CD4 (sCD4) and monoclonal
antibody (mAb) 17b, which has been used as a surrogate for
Fig. 3. D197 and T/V200 enhance the capacity of HIV Envs to use low CD4 for fusion with CCR5-expressing cells. (A) Cell surface expression of CD4 on transfected CF2-Luc cells
determined by ﬂow cytometry. (B–D) 293T cells expressing control ADA Env and parental Envs (B), M2br parental and mutant Envs (C), and UK1br parental and mutant Envs (D) were
mixed with CF2luc cells expressing low, intermediate, or high levels of CD4 as indicated. Fusionwas measured by analyzing luciferase activity at 5 (UK1br) or 8 h (M2br) depending on
the kinetics of fusion. Background luciferase activity, measured as luciferase activity for 293T cells expressing the nonfunctional ΔKS Env, was subtracted from each time point. Results
are expressed as mean percentages of fusion relative to the parental Env with cells expressing high CD4 and CCR5 and represent duplicate wells from a single experiment. Error bars
represent standard deviations. Experiments were repeated a minimum of 3 times for each Env set. *po0.05, Student's t-test.
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CCR5-binding, to probe conformational changes in gp120
(Zhang et al., 2001). Viruses expressing the M2br parental and
mutant Envs were resistant to neutralization by sCD4 at con-
centrations up to 50 μg/ml (Table 4 and Additional ﬁle 3),
consistent with published results (Kolchinsky et al., 2001a;
Rizzuto et al., 1998). UK1br Envs lacking the PNGS at position
197 (UK1br and UK1br T200V) were sensitive to sCD4 neutra-
lization, with IC50 values of 1.3 and 0.4 μg/ml, respectively. As
previously reported, the change to Asn at position 197 in the
UK1br Env increased resistance to sCD4 neutralization, with a
12-fold increase in the IC50 compared to the parental UK1br
(IC50¼16.0 μg/ml) (Huang et al., 2012; Kolchinsky et al., 2001a,
2001b; Li et al., 2008; Pantophlet et al., 2003). In contrast to
previous reports showing that loss of the PNGS at position 197
increased sensitivity of ADA and 89.6 Envs to 17b neutralization
(Kolchinsky et al., 2001a; Li et al., 2008; Rizzuto et al., 1998)
(Table 3), only the control virus expressing ADA Env was
neutralized by 17b, while those expressing UK1br and M2br
parental and mutant Envs were resistant to neutralization by
17b at concentrations up to 40 μg/ml (Table 4 and Additional ﬁle
3). Preincubation with a combination of sCD4 and 17b increased
neutralization sensitivity of viruses expressing M2br N197D and
N197D/V200T, with IC50 values of 26 and 0.22 μg/ml, respec-
tively. M2br Envs containing N197 and all UK1br Envs remained
resistant at concentrations of 17b up to 25 μg/ml. These results
suggest that changes in β3, including D197 in combination with
T/V200, may affect stability and/or exposure of the CCR5-
binding site following interactions with CD4.
Fig. 4. D197 and T/V200 enhance the capacity of HIV Envs to use low CD4 and CCR5 for virus entry. (A) Cell surface expression of CD4 and CCR5 on induced Afﬁnoﬁle cells
determined by ﬂow cytometry. Estimated CD4 and CCR5 antibody binding sites (ABS) on Afﬁnoﬁle cells were calculated using Quantibrite beads (Invitrogen). (B) Afﬁnoﬁle
cells were induced with 2-fold serial dilutions of doxycycline and Ponasterone A for 20 h, then infected with HIV luciferase reporter viruses pseudotyped with control ADA,
M2br and UK1br parental and mutant Envs. Infection was quantiﬁed after 48 h by analyzing luciferase activity. Background luciferase activity, measured as luciferase activity
for Afﬁnoﬁle cells infected with env-virus, was subtracted. Results are shown as contour plots depicting percentage of infection relative to cells expressing high CD4/high
CCR5 for virus expressing the parental Env. (C) Results are presented as percentage of infection relative to cells expressing high CD4 and CCR5 for virus expressing the
parental Env. *po0.05, Student's t-test.
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Discussion
In this study, integration of bioinformatic analysis of env
sequence datasets with functional studies identiﬁed naturally
occurring rare variants in the β3 strand of the HIV gp120 bridging
sheet that can increase macrophage tropism by enhancing gp120–
CCR5 interactions. D197, which results in loss of a PNGS located at
the HIV Env trimer apex that determines neutralization sensitivity/
resistance in several primary isolates (Kolchinsky et al., 2001b;
Li et al., 2008; O’Rourke et al., 2012; Pantophlet et al., 2003;
Rizzuto et al., 1998; Saphire et al., 2001), is a rare polymorphism
that was detected in brain in some patients with HAD. Codon 200
was estimated to be under positive selection in both brain and
lymphoid sequences from HAD patients. D197 and T/V200
enhanced fusion and infection of cells expressing low CD4,
including primary macrophages. In UK1br, T200V exhibited
increased sgp120 binding to CCR5, reaching levels 10-fold higher
than those of the parental Env. Requirements for CD4 and CCR5 are
interdependent, with requirements for each receptor being
increased when the other component is present at limiting levels
(Doms and Trono, 2000). Together, these ﬁndings suggest that β3
polymorphisms can enhance macrophage-tropism by increasing
gp120 interactions with CCR5 to overcome the restriction imposed
by low CD4 on macrophages.
The location of D197 and T/V200 in the gp120 bridging sheet,
their proximity to V3 of adjacent protomers at the trimer apex,
and our ﬁnding that these polymorphisms can increase HIV
infection of cells expressing low levels of CD4 and CCR5 suggest
that enhancement of infection in cells expressing low CD4 is most
likely due to increased afﬁnity of gp120 for CCR5. This model is
also supported by increased binding of monomeric UK1br T200V
sgp120 to cell-associated CCR5, and 10-fold increase in binding to
Fig. 5. V200 enhances macrophage entry mediated by UK1br HIV Env by increasing gp120 binding to CCR5. Soluble gp120 (sgp120) from UK1br wild-type and mutant Envs
was produced in 293T cells transfected with Env plasmids containing a stop codon at position 518. Concentrations of sgp120 in the supernatant were determined using ELISA
and veriﬁed by Western blotting. Concentrated sgp120 was incubated with CF2th–synCCR5 cells with or without preincubation with sCD4. Binding of sgp120 to CCR5 on the
cell surface was determined by ﬂow cytometry. Results are representative of 3 independent experiments. *po0.05, Student's t-test.
Table 4
Neutralization of parental and mutant HIV Envs by sCD4 and 17ba.
Virus sCD4 17b sCD4þ17b
ADA 1.7 4.4 ND
M2br 450 440 425
N197D 450 440 26.0
V200T 450 440 425
N197D/V200T 450 440 0.22
UK1br 1.3 440 425
D197N 16.0 440 425
T200V 0.4 440 425
a Values (μg/ml) represent IC50 values calculated from neutralization curves.
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CCR5 in the absence of CD4 compared to the parental Env (Fig. 5).
However, UK1br viruses with T200V did not mediate CD4-
independent fusion or infection, a ﬁnding that may reﬂect struc-
tural and functional differences between sgp120 monomers and
native Env trimers. In crystal and cryo-EM structures of the HIV
Env trimer (Julien et al., 2013; Lyumkis et al., 2013), the V3 crown
is buried under the N197 glycan from an adjacent protomer. Data
from these structures suggest that the N197 glycan helps to
stabilize the Env by occluding V3 and inhibiting its premature
release prior to CD4 binding. Thus, loss of the glycan in D197 may
affect V3 exposure upon CD4 binding, thereby inﬂuencing gp120–
CCR5 interactions.
The PNGS at 197 is highly conserved among clade A, B, C, and D
Envs (488%) (Huang et al., 2012). In the present study, sequence
polymorphisms that eliminate this PNGS were found in only 8% of
brain and 1% of blood/lymphoid Envs in the complete dataset of
796 sequences, indicating this variant is uncommon. Based on
previous studies (Huang et al., 2012; Kolchinsky et al., 2001a; Li
et al., 2008; Ly and Stamatatos, 2000), we expected to ﬁnd that
loss of the PNGS at 197 would increase exposure of the CCR5-
binding site and corresponding neutralization epitopes (Table 3).
Unexpectedly, viruses expressing UK1br and M2br Envs containing
D197 were not neutralization sensitive to mAb 17b even at high
concentrations. In contrast, incubation with both sCD4 and 17b
increased neutralization sensitivity of viruses expressing M2br
N197D and N197D/V200T (IC50¼26.0 and 0.2 μg/ml, respectively),
but not the UK1br Envs. In M2br, D197 and T200 may enhance
gp120 interactions with CCR5 by stabilizing the 17b epitope
following binding to CD4, consistent with a model proposed by
O’Connell et al. (2013). UK1br Envs were sensitive to neutralization
by sCD4, with increased neutralization resistance associated with
addition of the PNGS at position 197 (IC50¼16.0 and 1.3 μg/ml for
UK1br D197N and UK1br, respectively). These strain-dependent
differences in sCD4 neutralization sensitivity may relate to differ-
ences in intrinsic reactivity and propensity to sample different
conformations, which in turn may inﬂuence sCD4-induced sgp120
shedding and virus inactivation (Haim et al., 2009, 2011).
The strain-dependent effects of the PNGS at position 197 found
in the present study are consistent with previous studies reporting
strain-dependent effects of this PNGS on sensitivity to the entry
inhibitor BMS-806, several monoclonal antibodies (e.g., 17b, b3,
b12, F105, 2G12), and patient sera, as well as binding to sCD4 and
CCR5 (Gorry et al., 2002; Huang et al., 2012; Kolchinsky et al.,
2001a; Ly and Stamatatos, 2000; Madani et al., 2004; Pantophlet
et al., 2003; Pikora et al., 2005; Rizzuto et al., 1998; Saphire et al.,
2001). Furthermore, our results suggest that effects of D197 on
fusion and entry into cells expressing low CD4 can be additive
with those of T/V200. Structural models suggest that speciﬁc
residues in β3 (D197, T198, and V200) may affect interactions
with the variable V3 loop in a cooperative manner (Ly and
Stamatatos, 2000; Pan et al., 2005; Zhu et al., 2001). Topological
relationships of these amino acids to each other, and to V1/V2 and
V3 elements near the trimer apex and inter-protomer interface
may help to explain some of the unexpected ﬁndings for V200T
and T200V; these structural relationships are complex, so amino
acid variation at these positions could exert different phenotypes
depending on sequence variation in nearby residues. Together,
these observations suggest that strain-dependent effects of β3
residues on neutralization sensitivity and macrophage-tropism
may reﬂect amino acid covariation and/or context dependence in
these regions.
Genetic evolution of HIV Env occurs in response to in vivo
selection pressures that include adaptation to target cell popula-
tions and immune evasion. The speciﬁc selection pressures that
drive changes in M-tropism of R5 Envs in vivo are poorly under-
stood (Richards et al., 2010). Analysis of diversifying selection in
the bridging sheet region of the CCR5-binding site in gp120
identiﬁed position 200 as a codon in the bridging sheet under
positive selection in both brain and blood/lymphoid sequences in
sequences from HAD patients. We did not detect positive selection
at this position in non-HAD patients; however, this difference
could be a result of the different numbers of sequences between
HAD (336 sequences from 19 subjects) and non-HAD groups (119
sequences from 11 subjects), which is a limitation of the study.
Position 200 is located in several overlapping immunodominant
cytotoxic T lymphocyte (CTL) epitopes (http://www.hiv.lanl.gov/
content/immunology/index.html); diversifying selection at this
position may therefore be a consequence of immune evasion. A
better understanding of host and immune selection pressures that
shape the genetic evolution of HIV in brain and other tissues is
important not only for understanding mechanisms of viral persis-
tence in the CNS reservoir, but also for developing new strategies
to prevent HIV-related neurocognitive dysfunction.
Conclusions
In summary, polymorphisms in the β3 strand of the HIV gp120
bridging sheet can increase macrophage tropism by enhancing
gp120 interactions with CCR5. T/V200 can enhance fusion and
virus entry when combined with D197, suggesting covariation and
sequence context inﬂuence this phenotype. Requirements for CD4
and CCR5 are interdependent, with the requirement for each
receptor being increased when the other is present at limiting
levels (Doms and Trono, 2000). By enhancing Env interactions
with CCR5, these polymorphisms may enable viruses to overcome
the restriction to macrophage infection imposed by low CD4,
thereby promoting infection of the CNS and other macrophage-
rich tissues.
Methods
Sequence analysis
Nucleotide sequences from published studies and Genbank
were aligned using ClustalX2. HIV gp120 sequences spanning the
V1–V5 region were examined using three different methods to
identify codons under positive selection: single likelihood ancestor
counting (SLAC), ﬁxed-effects likelihood (FEL), and internal ﬁxed
effects likelihood (IFEL) (http://datamonkey.org). SLAC and FEL
detect sites under selection at external branches of the phyloge-
netic tree, while IFEL identiﬁes sites along internal branches (Pond
and Frost, 2005; Pond et al., 2006, 2008). Sites were classiﬁed as
positively selected when a signiﬁcant p-value (po0.05) was
estimated by at least 2 of these methods. To identify viral
determinants associated with brain compartmentalization or
dementia, gp120 β2 and β3 amino acid sequences were aligned
using ClustalX2. Exploratory analyses of amino acid distributions
using large sequence datasets accounted for the variable number
of sequences per patient using stratiﬁed 22 contingency tables
to weight sequence variants within each patient, and normalizing
for differences in sequencing depth between patients. Statistical
analysis of β3 amino acid distributions was then performed using
a ﬁltered dataset consisting of one randomly selected sequence per
patient. p Values were assigned using Fisher's exact test, with
po0.05 considered signiﬁcant. Previously unpublished sequences
were deposited in Genbank [Genbank: HQ122390–HQ122408;
HM355533–HM355546].
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Cells
293T and TZM-bl cells, a HeLa cell clone engineered to express
CD4 and CCR5 that contains integrated reporter genes for ﬁreﬂy
luciferase and E. coli β-galactosidase under control of HIV-1 LTR,
were cultured in DMEM media supplemented with 10% (v/v) fetal
bovine serum (FBS) and 100 μg/ml penicillin and streptomycin.
CF2-Luc cells, which are derived from canine thymocyte cell line
CF2th and stably express ﬁreﬂy luciferase under control of HIV-1
LTR (Etemad-Moghadam et al., 2000), and CF2th–synCCR5 cells,
which express a codon-optimized version of human CCR5 contain-
ing a C-terminal nonapeptide (TETSQVAPA) tag derived from
bovine rhodopsin (Gorry et al., 2002), were cultured in medium
supplemented with 0.7 mg/ml G418 (Mediatech, Herndon, VA).
Afﬁnoﬁle cells were cultured in DMEM supplemented with 10%
dialyzed FBS (Gibco, Grand Island, NY), 100 μg/ml penicillin and
streptomycin, and 50 μg/ml blasticidin S HCl (Invitrogen, Grand
Island, NY) (Johnston et al., 2009). Monocyte-derived macrophages
(MDM) were derived from peripheral blood mononuclear cells
(PBMC) isolated from healthy HIV-negative donors. As previously
described, MDM were isolated from PBMC by plastic adherence
and cultured in RPMI 1640 medium supplemented with 10% FBS,
100 μg/ml penicillin and streptomycin, and 10 ng/ml macrophage
colony stimulating factor (M-CSF, R&D Systems, Minneapolis, MN)
(Gorry et al., 2002). TZM-bl cells were provided by Norman Letvin.
Afﬁnoﬁle cells were provided by Benhur Lee.
Viruses and mutagenesis
Primary clade B env genes from AIDS patients with HAD were
cloned into pCR3.1 as previously described (Gorry et al., 2002;
Thomas et al., 2007). Env expression and processing were veriﬁed
by Western blotting with goat anti-gp120 (AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH,
Bethesda, MD) (Dunfee et al., 2006b; Sterjovski et al., 2007).
Mutant Env plasmids with changes at positions 197 and 200
(HXB2 numbering) were created by PCR-based mutagenesis and
veriﬁed by DNA sequencing.
Entry assays
HIV luciferase reporter viruses were generated by cotransfec-
tion of 293T cells with pNL4-3env-luc, an HIV provirus with env
deleted and nef replaced with luciferase, and an Env-expressing
plasmid as described (Gorry et al., 2002). TZM-bl cells were seeded
into 96-well plates in media supplemented with 15 μg/ml DEAE-
dextran and infected with 104 3H cpm reverse transcriptase (RT)
units of virus stock. Cells were lysed 48 h post-infection and
assayed for luciferase activity. MDM were prepared in 48-well
plates and infected overnight with 2104 RT units of virus stock
in media supplemented with 2 μg/ml polybrene. Cells were lysed
6 days post-infection and assayed for luciferase activity. Afﬁnoﬁle
cells were seeded into 96-well plates and treated for 20 h with
serial dilutions of 3–0.09 ng/ml doxycycline (Clontech, Mountain
View, CA) to induce CD4 expression and 2–0.06 μM Ponasterone A
(Invitrogen) to induce CCR5 expression (Johnston et al., 2009).
Cells were then infected with 104 RT units of virus stock, lysed
2 days post-infection, and assayed for luciferase activity. Mock
infected cells were used as negative controls. Background lucifer-
ase levels were subtracted from all results.
Fusion assays
293T cells were cotransfected with 2 μg pCR3.1 Env-expressing
plasmid and 0.2 μg pLTR-Tat using calcium phosphate. Cf2-Luc
cells were cotransfected with 0.1 (low), 1 (intermediate), or 10 μg
(high) amounts of pcDNA3–CD4 and 10 μg (high) pcDNA3–CCR5
using Lipofectamine 2000 (Invitrogen). 2.5104 293T cells and
2.5105 CF2-Luc cells were mixed in 48-well plates and incubated
for 5–8 h. Cells were then lysed and analyzed for luciferase
activity. 293T cells cotransfected with a nonfunctional Env
(pSVIII-ΔKSenv) and pLTR-Tat were used to determine back-
ground levels of luciferase.
Flow cytometry
Cell surface expression of CD4 and CCR5 on induced Afﬁnoﬁle
and transfected CF2-Luc cells was analyzed by collecting cells with
5 mM EDTA in PBS and staining with anti-CD4-PE (BD Biosciences,
San Jose, CA) and anti-CCR5-PE (BD Pharmingen, San Diego, CA).
Cell surface staining was analyzed using a FACSCantoII ﬂow
cytometer (BD Biosciences). The approximate number of CD4
and CCR5 molecules per cell was calculated using FACS analysis
of Quantibrite beads according to manufacturer's instructions (BD
Biosciences).
ELISA
ELISAs were based on previously described methods (Bowley
et al., 2007; Moore et al., 2008; Si et al., 2004) with several
modiﬁcations. Brieﬂy, 96-well microplates were coated overnight
with sheep antibody D7324 at 5 μg/ml in PBS (AALTO Bioproducts,
Ltd., Ireland). Wells were washed 3 times with PBS supplemented
with 2.5% Tween-20 (PBS-T) and blocked for 1 h at room tem-
perature with PBS-T supplemented with 3% BSA. Supernatants
were incubated in the wells for 3 h, followed by 10 washes with
PBS-T and 1 h incubation with polyclonal rabbit anti-gp120 (Amer-
ican Biotechnologies Inc.). After 10 additional washes with PBS-T,
wells were incubated with anti-rabbit-HRP (GE Healthcare). The
reaction was developed using BM chemiluminescence ELISA sub-
strate (Roche) according to the manufacturer's instructions. The
reaction was read on a luminometer (Viktor2, Perkin Elmer,
Waltham, MA). Calculations of sgp120 concentrations were based
on a standard curve of puriﬁed gp120 (Dunfee et al., 2006b).
Supernatant from cells transfected with empty pcDNA3 vector was
used to determine background.
CCR5-binding assays
Plasmids expressing soluble gp120 (sgp120) glycoproteins were
constructed by introducing a frameshift in gp120 that resulted in a
truncation at position 518 (HXB2 numbering). Supernatants from
293T cells transfected with the Env-expressing plasmids were
collected 48 h post-transfection and cleared by centrifugation at
2000 rpm for 5 min. Supernatants were stored at 80 1C. Super-
natants were concentrated by centrifugation using Amicon Ultra
columns with a 30-kD cutoff (Millipore, Billerica, MA). Sgp120
concentrations in concentrated supernatants were determined by
ELISA. Equal concentrations of sgp120 were incubated with or
without 1 μg/ml soluble CD4 (sCD4, Immunodiagnostics, Woburn,
MA) for 30 min at 37 1C prior to incubation with CF2-synCCR5
cells. Binding of sgp120 to cells was detected by staining with mAb
C11, followed by anti-human-PE (Bio-Rad, Hercules, CA), and was
analyzed by ﬂow cytometry. Speciﬁcity of gp120 interaction with
CCR5 was veriﬁed by pre-incubating CF2-synCCR5 cells with
100 nM TAK-779 (obtained through the AIDS Research and Refer-
ence Reagents Program, Bethesda, MD) (Baba et al., 1999) for 1 h at
37 1C prior to incubation with sgp120.
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Neutralization assays
HIV luciferase reporter viruses were incubated with a range of
concentrations of sCD4, monoclonal antibody (mAb) 17b (NIH
AIDS Research and Reference Reagent Program, donated by
Dr. James E. Robinson), or 0.1 μg/ml sCD4 and a range of concen-
trations of 17b in combination for 1 h at 37 1C prior to infection of
TZM-BL cells. Cells were harvested 48 h post-infection and assayed
for luciferase activity (Binley et al., 2004).
Statistical analysis
Statistical signiﬁcance in experiments comparing parental and
mutant Envs was determined using Student's unpaired 2-tailed
t-test, with results presented as means of duplicate wells from a
single experiment. Bars represent standard deviations. p-Valueso
0.05 were considered signiﬁcant.
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